356 related articles for article (PubMed ID: 16248830)
21. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
[TBL] [Abstract][Full Text] [Related]
22. [PPAR and diabetes].
Terauchi Y; Kadowaki T
Nihon Rinsho; 2005 Apr; 63(4):623-9. PubMed ID: 15828230
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Staels B; Fruchart JC
Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
[TBL] [Abstract][Full Text] [Related]
24. Tesaglitazar: a promising approach in type 2 diabetes.
Cox SL
Drugs Today (Barc); 2006 Mar; 42(3):139-46. PubMed ID: 16628256
[TBL] [Abstract][Full Text] [Related]
25. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis.
Leahy JL
Curr Diab Rep; 2009 Jun; 9(3):215-20. PubMed ID: 19490823
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
27. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
Larsen TM; Toubro S; Astrup A
Int J Obes Relat Metab Disord; 2003 Feb; 27(2):147-61. PubMed ID: 12586994
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
30. Thiazolidinediones--tools for the research of metabolic syndrome X.
Komers R; Vrána A
Physiol Res; 1998; 47(4):215-25. PubMed ID: 9803467
[TBL] [Abstract][Full Text] [Related]
31. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
32. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
33. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
Dubois M; Vantyghem MC; Schoonjans K; Pattou F
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
[TBL] [Abstract][Full Text] [Related]
34. [Effects of PPARgamma agonist on dyslipidemia and atherosclerosis].
Komatsu A; Node K
Nihon Rinsho; 2010 Feb; 68(2):294-8. PubMed ID: 20158099
[TBL] [Abstract][Full Text] [Related]
35. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
Tanaka T
Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological treatment of insulin resistance in obesity.
Camejo G; Ljung B; Oakes N
Nutr Metab Cardiovasc Dis; 2001 Aug; 11(4):275-84. PubMed ID: 11831112
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
39. Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists.
Cha BS; Ciaraldi TP; Park KS; Carter L; Mudaliar SR; Henry RR
Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E151-9. PubMed ID: 15727952
[TBL] [Abstract][Full Text] [Related]
40. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.
Pershadsingh HA
Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
